Deregulated expression of the proto-oncogene c-myb, which results from provirus integration, is thought to be responsible for transformation in a set of murine leukemia virus (MuLV)-induced myeloid leukemias (MML). We reported recently that this transcription factor promotes proliferation by directly transactivating c-myc and inhibits cell death through its up-regulation of Bcl-2 (Schmidt et al., 2000) . To understand more about how these cells become transformed we looked at how they deal with cellular pathways inducing growth arrest. Speci®cally, we were interested in the expression of the tumor suppressor gene Cdkn2b (p15 INK4b ) in MML because this gene is expressed during myeloid dierentiation and its inactivation by methylation has been shown to be important for the development of human acute myeloid leukemia. mRNA levels for p15 INK4b and another INK4 gene p16
INK4a were examined in monocytic Myb tumors and were compared with expression of the same genes in c-myc transformed monocytic tumors that do not express c-Myb. The Cdkn2a (p16
INK4a
) gene was generally not expressed in either tumor type, an observation explained by methylation or deletion in the promoter region. Although Cdkn2b (p15 INK4b ) mRNA was expressed in the Myc tumors, many transcripts were aberrant in size and contained only exon 1. Surprisingly, in the majority of the Myb tumors there was no p15
INK4b transcription and neither deletion nor methylation could explain this result. Additional experiments demonstrated that, in the presence of constitutive c-Myb expression, the induction of p15
Introduction
Myeloid leukemias arise in adult BALB/c or DBA/2 mice following infection with replication competent retroviruses if the mice are additionally undergoing a chronic peritoneal in¯ammation. This observation has been exploited in a murine disease model to investigate events required for development of these leukemias, commonly referred to as MML for murine leukemia virus (MuLV) induced myeloid leukemia. The leukemias are promonocytic and resemble, both morphologically and biochemically, acute monocytic leukemia-M5 in humans. An important step in the development of MML is deregulated expression of c-myb in these tumors, which results from retrovirus integration into the c-Myb locus (Shen-Ong and Wol, 1987; Wol et al., 1988 Wol et al., , 1991 Wol et al., , 1996 Nason-Burchenal and Wol, 1993; Wol, 1996) . The c-Myb protein is a transcription factor involved in regulation of cell growth, apoptosis and dierentiation of hematopoietic cells (Oh and Reddy, 1999) . In transformed cells, c-Myb causes deregulated expression of the antiapoptotic gene bcl-2 as well as of the growth regulators c-myc and c-kit (Evans et al., 1990; Zobel et al., 1992; Cogswell et al., 1993; Frampton et al., 1996; Taylor et al., 1996; Hogg et al., 1997; Ratajczak et al., 1998; Schmidt et al., 2000) .
It is not known if the loss of tumor suppressor function is necessary for MML development (Weinberg, 1997) . This is interesting in light of recent reports that the Cdkn2a and 2b genes that encode p16
INK4a and p15
INK4b
are frequently inactivated in human leukemia either by deletion of the gene locus or methylation of the promoter region (Herman et al., 1996; Batova et al., 1997; Malumbres et al., 1997; Drexler, 1998) . p16 INK4a and p15
INK4b have each been identi®ed as inhibitors of the cyclin D/cyclin dependent kinase 4 and 6 complexes, preventing phosphorylation of RB and the release of active E2F and therefore can block cells in the G1 phase of the cell cycle (Siebert et al., 1996) . Cdkn2a ( p16 INK4a ) is one of the most frequently altered genes in cancers of all types (Hirama and Koeer, 1995) and its de®nition as a tumor suppressor has been reinforced by studies of knockout mice that develop B cell lymphomas (Serrano et al., 1996) . Compared to Cdkn2a (p16 Ink4a ), the role of Cdkn2b (p15
Ink4b
) as a tumor suppressor is less clear. Knockout Oncogene (2001) 20, 6205 ± 6214 ã 2001 Nature Publishing Group All rights reserved 0950 ± 9232/01 $15.00 www.nature.com/onc mice develop lymphoproliferative disease and low incidence of hematopoietic neoplasms (Latres et al., 2000) . In addition, p15
Ink4b was recently shown to be a strong inhibitor of Ras transformation of NIH3T3 cells . The gene's up-regulation is correlated with speci®c biological responses such as dierentiation of myeloid cells into macrophages and neutrophilic granulocytes (Schwaller et al., 1997; Teo®li et al., 1998) . In vitro, it is induced in myeloid cells following IL-6 stimulation and up-regulated in epithelial cells by transforming growth factor b (TGFb1) (Hannon and Beach, 1994) .
To determine if loss of either Cdkn2a or 2b plays a role in the development of MML, we evaluated the expression of these genes in several of our monocytic tumors with deregulated c-Myb. The results were compared with those obtained for c-Myc transformed monocyte-macrophage tumors that do not express cMyb (Wol et al., 1988) . We show that Cdkn2a (p16
INK4a
) is deleted or methylated in both tumor types, a result which is similar to data obtained for human leukemias. The surprising ®nding was that although Myb tumors show little or no expression of p15 
Results

Expression of p16
INK4a and analysis of the Cdkn2a genetic locus Experiments were carried out to determine if, as in human leukemias, the Cdkn2 locus (Figure 1) To see if lack of expression of this gene was due to methylation or deletion, we digested genomic DNA with EcoRI and the methylation sensitive restriction enzyme XhoI (Figure 1 ). We found evidence for methylation in the Cdkn2a promoter region in three Myb tumors and deletion in two tumors (Table 1, Figure 5 ). The fact that we did not observe p16 INK4a RNA expression in any of the Myb tumors could now be explained at least in part by these alterations. For Figure 1 Physical map of the Cdkn2a (INK4a) and Cdkn2b (INK4b) gene locus. Shown are the fragments expected to result from digestion of genomic DNA with EcoRI and the methylation sensitive restriction enzymes XhoI or EagI the Myc tumors, analysis of this locus also correlated with the mRNA expression data. We found evidence for methylation in one tumor and evidence for deletion in an additional four, accounting for lack of expression in six out of seven examples.
Expression of p15
INK4b and analysis of the Cdkn2b genetic locus Table 2 ). The RNAs give rise to the full length protein as shown in Figure 3 for the tumor cell lines 2-2-2 and 5-2-5 and can therefore be expected to be functional. As expected, no protein was detected for the Myb tumor 30A6-26. M1 cells dierentiating in the presence of IL-6 were used as a positive control. Interestingly, in two of the Myc tumors, an aberrant product, smaller than the normal 1.3 kb mRNA of p15 INK4b was evident. This RNA could easily be hybridized with a probe speci®c for exon 1, but not with a probe for exon 2. Because the size of these transcripts is bigger than that of exon 1, it suggests that most of them may have arisen from an alternative splicing mechanism (Figure 4 ). It was no surprise that an examination of the Cdkn2b (p15
INK4b
) locus in the Myc tumors did not uncover evidence of methylation. This was predicted because most tumors expressed mRNA for p15
INK4b (Table 2, Figure 5 ). Of the two tumors, which lacked expression, one (6-3-9) had evidence of deletion in the promoter region.
Of particular interest was the fact that, although the Myb tumors generally lacked expression of p15
, there were no signs of methylation to account for the defect. No methylation was detected at the methylation sensitive restriction enzyme sites XhoI and EagI as INK4b cDNA probe or a probe covering exon 1 of p16
INK4a
. To control for sample loading the same blot was rehybridized with a b-actin probe ) locus
mRNA expression as determined by Northern blot analysis. b Methylation status was determined using restriction enzyme digestion; enzymes used were EcoRI+XhoI. Figure  5 ). This could have been a consequence of deletion of the Cdkn2a (p16 INK4a ) region since the two genes reside side by side on the chromosome. Loss of the two genes by a single deletion has been observed before, as reviewed by HG Drexler (1998) .
The surprising result from the above examination of tumor DNA was the lack of methylation in the Cdkn2b gene in Myb tumors that did not express the p15
INK4b mRNA. There was a possibility that we had failed to detect methylation in these tumors, because we were examining a limited number of CpGs. To rule out this possibility we looked for methylation using bisulphite genomic sequencing. This technique allows one to evaluate the methylation status of every C in a selected region. A physical map showing the CpG densities of the Cdkn2b (p15
INK4b
) murine promoter region was published recently (Malumbres et al., 1997) . Two sets of primers from the murine p15
INK4b region, as shown in Figure 1 , were used for analysis, allowing us to examine a total of 55 CpGs. The human leukemic cell line KG1a, reported by Cameron et al. (1999) to be heavily methylated, was used as a positive control to con®rm that the technique itself worked (Figure 6 ). We examined three Myb tumors originating from BALB/c mice and two from DBA/2 mice ( Figure 6 ). Following bisulphite treatment, ampli®cation and cloning of the ampli®ed products, we sequenced 4 ± 8 clones from each tumor. We found either no methylated CpG sites or only one methylated site in each of the clones analysed. The overall methylation for each tumor varied from 0.0 ± 0.8%. Since methylation of approximately 40% of all CpGs in this promoter region have been shown previously to correlate with the inactivation of p15 INK4b expression (Cameron et al., 1999) , the lack of expression in the Myb tumors cannot be explained by CpG methylation.
p15
INK4b expression is inhibited in M1 cells constitutively expressing c-myb but not in M1 cells expressing c-myc
The above results suggested that constitutive expression of c-Myb might play a role in the loss of p15 INK4b expression. To test this possibility experimentally, we examined the eect of c-Myb on p15
INK4b expression in Predominant small transcript which hybridizes with exon 1 but not exon 2. c Methylation status was determined using restriction enzyme digestion; two sets of enzymes were used: EcoRI+EagI; EcoRI+XhoI. INK4b . Using a monoclonal antibody against p15
INK4b the tumor suppressor was detected in the protein lysate of tumor cell lines as well as in dierentiating M1 cells. M1 cells and M1 cells treated with IL-6 were used as a control. 30A-6-26 is a Myb tumor, 2-2-2 and 5-2-5 are Myc tumors a cell line capable of dierentiating toward the monocytic lineage. We used the myeloblastic cell line M1 that undergoes terminal dierentiation to a mature macrophage phenotype over the course of 3 ± 4 days, if cultivated in the presence of IL-6. In this system, growth arrest occurs 2 ± 3 days following induction, and cell death through apoptosis occurs 5 ± 7 days post stimulation. During the course of dierentiation, c-myb expression is down-regulated by 3 h and c-myc expression is reduced to undetectable levels by 24 h (Selvakumaran et al., 1992) . Analysis of cells for p15
INK4b mRNA expression revealed that this gene is turned on by 3 h following treatment with IL-6 ( Figure  7 ) and is therefore temporally correlated with the down-regulation of c-myb. Activation of p15 INK4b expression during dierentiation of myeloid cells has been reported previously for the human leukemic cell line HL60 (Schwaller et al., 1997) . These observations are also in agreement with a recent report linking p15
INK4b expression to granulocyte-monocyte dierentiation (Teo®li et al., 1998) .
Next, we looked speci®cally at the eect of constitutively expressed c-myb (M1/c-Myb) or B-myb (M1/B-Myb) on p15
INK4b expression in M1 cells as these cells, unlike normal M1 cells, do not terminally dierentiate or growth arrest following IL-6 treatment . While ecotopic expression of B-myb did not prevent activation of p15
INK4b expression during IL-6 induced dierentiation, constitutive expression of c-myb interfered with its induction (Figure 7 ). To con®rm that this eect was due to c-myb and not to alterations in the gene locus we examined the p15 INK4b promoter region of these cells. Bisulphite genomic sequencing did not detect a signi®cant amount of methylation that could be responsible for the observed interference in the activation of the gene. There were no C's methylated in four of ®ve analysed clones, and in the ®fth clone we detected methylation in only four . Two mg of Poly(A) + RNA from Myc tumors which showed expression of an alternative p15 transcript was separated on an agarose gel, blotted on nitrocellulose and hybridized with a probe consisting of exon 1 of p15
INK4b
. The same blot was stripped and rehybridized with an exon 2 probe Figure 5 Gene rearrangements and methylation in the Cdkn2 (INK4) locus. Ten mg of genomic DNA from Myc and Myb tumors was digested with EcoRI and XhoI, separated on an agarose gel, blotted on nitrocellulose and hybridized with a full length cDNA probe for p16
INK4a or a p15 INK4b probe as shown in Figure 1 of the 55 CpGs examined (Figure 6 ). Additionally, neither the bisulphite genomic sequencing nor Southern blot analysis (data not shown) revealed deletions or rearrangements in the p15 INK4b region of the M1/c-Myb cells that could account for the inability to induce expression of the tumor suppressor.
Since MML express N-or C-terminally truncated forms of c-Myb, we decided to look at the eect of their constitutive expression on p15
INK4b expression. M1 cells constitutively expressing N-(747 aa) or C-(7248 aa) -terminally truncated versions of c-Myb (Bies et al., 1995) were, like full length c-Myb, unable to up-regulate p15 INK4b in response to IL-6 (Figure 8 ).
Interestingly, p15
INK4b expression could still be observed in dierentiating M1 cells expressing a conditionally active c-myc (M1/MycER) (Figure 9 ). This suggests that it is not Myb's ability to transactivate c-myc, that is responsible for the repression. 
Discussion
In the study presented here, the expression of the Cdkn2 (INK4) genes encoding the tumor suppressors p16
INK4b
, was examined in monocytic leukemias that inappropriately express c-Myb or cMyc. An overall ®nding was a lack of transcription or presence of aberrant mRNAs. Since these tumor suppressors play an important role in AML in man, these experiments further illustrate the utility of this tumor model for the human disease.
The most intriguing ®nding of the study was a lack of p15
INK4b gene transcription in Myb tumors that could not be explained by alterations in the gene locus. This leads us to propose that there are alternative mechanisms to account for p15 INK4b inactivation. Although deletion or methylation in the promoter region of the gene is observed frequently in human AML (Herman et al., 1996; Drexler, 1998) , we found no evidence for these types of changes. Instead, the lack of expression appeared to be due to speci®c in¯uences of c-Myb on p15
INK4b transcription. This result was borne out experimentally in in vitro experiments showing that three forms of c-Myb, but not B-Myb, interfere with up-regulation of p15
INK4b in dierentiating myeloid cells.
At this point it is not clear whether c-Myb has a direct or indirect in¯uence on the Cdkn2b (p15   INK4b   ) promoter. We have evidence that the inhibition is not indirectly due to c-myc, a transcriptional target of cMyb, because p15
INK4b transcription is not inhibited by c-Myc (data presented here and recently published data of Amanullah et al., 2000) . This is in contrast to data reported by Seoane et al. (2001) and Staller et al. (2001) as they were able to demonstrate that activation of p15
INK4b is repressed by c-Myc in ®broblasts. This would indicate that this function of c-Myc is cell type dependent. Taking into account these results, Myb's ability to in¯uence p15
INK4b expression may prove to be unique for the hemapoietic lineage. Furthermore, we 3, 7, 14 and 24 h following treatment with IL-6 the cells were harvested, total RNA was isolated, separated on an agarose gel, blotted on nitrocellulose and hybridized with a p15
INK4b cDNA probe. To control for sample loading the same blot was rehybridized with bactin
Figure 8 p15
INK4b mRNA expression is inhibited in cells constitutively expressing truncated forms of c-Myb. M1, M1/cMyb, M1/NT-trunc Myb, M1/CT-trunc Myb cells were cultivated in the presence of IL-6 for 0, 3, 7, 14 and 24 h. Total RNA was isolated from the samples, separated on an agarose gel, blotted on nitrocellulose and hybridized with a p15
INK4b cDNA probe. To control for sample loading the same blot was rehybridized with bactin have not been able to demonstrate an inhibitory in¯uence of c-Myb itself on the p15
INK4a promoter using reporter gene assays (data not shown), although we cannot completely rule out the possibility that it has a direct eect. The in¯uence of c-Myb may be indirect through, for example, transactivation of a repressor of the p15
INK4b promoter. One might speculate that c-Myb prevents a general growth arrest pathway from being turned on during dierentiation, even though c-Myb does not inhibit development of the monocytic phenotype itself as reported previously Wol et al., 1996) .
The loss of p15 INK4b transcription in Myb, but not Myc tumors is interesting because both tumor types are essentially at the same developmental stage. However, the presence of truncated transcripts lacking exon 2 in several of the tumors indicates a tendency for the gene to be inactivated in the Myc tumors as well. Although, the three dimensional structure of p15
INK4b has not been determined, it can be assigned, based on sequence homology, to the family of ankyrin repeat proteins like other members of the INK4 family p16
INK4a
, p18
INK4c and p19
INK4d
. Based on this sequence homology p15
INK4b is predicted to contain three and a half ankyrin repeats (Zhang and Peng, 2000) . The loss of exon 2 which is part of the ankyrin repeats would be predicted to disrupt the secondary and tertiary structure of this protein.
In view of our earlier ®nding that c-Myb regulates the expression of c-myc both in the M1 dierentiation model and in MML leukemias (Myb tumors) (Schmidt et al., 2000) , we speculate that inhibition of INK4 genes in these cells is additionally required for the activation of the endogenous c-myc promoter. This speculation is based on evidence from other laboratories that E2F is required for c-myc promoter activity (Ragione and Iolascon, 1997), which makes it likely that its presence is required for c-Myb to eciently activate the c-myc promoter. The INK4 proteins, through their inhibition of RB phosphorylation, cause RB to be bound to E2F, which results in recruitment of repression factors to the c-myc promoter. Therefore, it would be necessary to prevent the up-regulation of INK4 proteins in conjunction with inappropriate expression of c-Myb to maintain transcription of cmyc. This is the opposite situation to that which occurs during normal dierentiation of monocytes where cMyb is down-regulated and p15
INK4b is up-regulated. Our picture of how c-Myb transforms cells is beginning to emerge. Data presented here suggests that one way c-Myb promotes cell growth is by inhibiting tumor suppressor activation. Another way c-Myb positively regulates cell growth is by directly transactivating the proliferation genes c-myc and c-kit (Hogg et al., 1997; Schmidt et al., 2000) . Although we did not detect expression of the stem cell growth regulator c-Kit in the dierentiated monocytic tumor cells with constitutively expressed c-Myb, c-Kit may be involved in transformation of more immature target cells, such as fetal liver cells studied by Hogg et al. (1997) and during preleukemic stages in our tumor model (Nason-Burchenal and Wol, 1993) . In addition to promoting cell growth, c-Myb can counteract apoptosis by up-regulating the anti-apoptotic gene Bcl-2 (Frampton et al., 1996; Taylor et al., 1996; Schmidt et al., 2000) , thus keeping cells with proliferative potential alive and counteracting apoptotic eects of Myc over-expression (Thompson, 1998) . It is likely that c-Myb, in addition to the genes mentioned here, regulates additional genes that could contribute to Myb's known roles in cell cycle progression and anti-apoptosis.
Materials and methods
Cells, tumors and virus
The Myb tumors used in this study were induced by infecting BALB/c mice with Moloney murine leukemia virus or DBA/2 mice with the amphotropic murine retrovirus (4070A) (Wol et al., 1988 (Wol et al., , 1991 . The Myc tumors were induced by infecting BALB/c mice with a c-myc expressing, Moloney MuLV- INK4b mRNA induction in dierentiating M1/MycER cells. M1/MycER cells were cultivated in the presence of IL-6. MycER was activated by treating the cells with 2 nM 4-hydroxytamoxifen (4-OHT). 0, 3, 7, 14 and 24 h following treatment with IL-6 or IL-6 and 4-OHT the cells were harvested, total RNA was isolated, separated on an agarose gel, blotted on nitrocellulose and hybridized with a p15
INK4b cDNA probe. To control for sample loading the same blot was rehybridized with b-actin based retroviral vector (Wol et al., 1988) . RNA or genomic DNA was isolated directly from tumor tissue or in the case of 30A-1-2, 30A-3-12, 30A-3-14 and 30A-6-26 from cell lines established from these tumors.
The human myeloid progenitor cell line, KG1a (a kind gift of F Ruscetti), was maintained in RPMI 1640 medium supplemented with 10% heat-inactivated fetal calf serum. The murine myeloid cell line M1 (Liebermann and HomanLiebermann, 1989 ) was maintained in RPMI 1640 medium supplemented with 10% heat-inactivated horse serum. Construction of the retroviral vectors expressing full length, C-terminally or N-terminally truncated c-myb as well as Bmyb and characterization of the cell lines infected with these vectors has been described (Bies et al., 1995 Wol et al., 1996) . For M1 cell dierentiation, cells were seeded at a concentration of 1 ± 2610 5 /ml in medium containing IL-6. IL-6 stocks were prepared as described recently (Schmidt et al., 2000) .
Preparation of RNA and Northern blot analysis
Total RNA was prepared using a RNAeasy Mini Kit (Qiagen). Poly(A) + RNA was prepared as described before (Bies et al., 1995) from 5610 7 ± 1610 8 cells, using a modi®cation of a procedure reported by Badley et al. (1988) . Five mg samples of total RNA or 2 mg samples of Poly(A) + RNA were electrophoresed in a Tris acetate EDTA buer on a 1.0% agarose gel containing 20 mM guanidine thiocyanate as described in Goda and Minton (1995) . After blotting to a nylon membrane, the RNA was crosslinked to the membrane using a Stratalinker 1800 (Stratagene). Probes used for hybridization were labeled using a random priming kit (GIBCO ± BRL). The following DNA fragments were used as probes: cDNA for p15
INK4b (Quelle et al., 1995) 
